Clinical Trial Update: 99mTc-3PRGD2 SPECT/CT for Integrin Imaging of Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the diagnostic imaging agent 99mTc-3PRGD2 SPECT/CT for integrin imaging in lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Lymph Node Metastasis

Drugs mentioned

• 99mTc-3PRGD2 SPECT/CT imaging agent (99mTc-3PRGD2)

Snippet

Sponsor: RDO Pharm. | Conditions: Lung Cancer, Lymph Node Metastasis | Phase 3 | Status: COMPLETED